Location of Repository

Hypothalamic Obesity after Craniopharyngioma: Mechanisms, Diagnosis, and Treatment

By Robert H. Lustig


Obesity is a common complication after craniopharyngioma therapy, occurring in up to 75% of survivors. Its weight gain is unlike that of normal obesity, in that it occurs even with caloric restriction, and attempts at lifestyle modification are useless to prevent or treat the obesity. The pathogenesis of this condition involves the inability to transduce afferent hormonal signals of adiposity, in effect mimicking a state of CNS starvation. Efferent sympathetic activity drops, resulting in malaise and reduced energy expenditure, and vagal activity increases, resulting in increased insulin secretion and adipogenesis. Lifestyle intervention is essentially useless in this syndrome, termed “hypothalamic obesity.” Pharmacologic treatment is also difficult, consisting of adrenergics to mimic sympathetic activity, or suppression of insulin secretion with octreotide, or both. Recently, bariatric surgery (Roux-en-Y gastric bypass, laparoscopic gastric banding, truncal vagotomy) have also been attempted with variable results. Early and intensive management is required to mitigate the obesity and its negative consequences

Topics: Endocrinology
Publisher: Frontiers Research Foundation
OAI identifier: oai:pubmedcentral.nih.gov:3356006
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2006). A multimodality approach to the treatment of craniopharyngiomas avoiding hypothalamic morbidity: a UK perspective.
    2. (2001). Activation of the parasympathetic nervous system is necessary for normal meal induced-insulin secretion in rhesus macaques.J.Clin.Endocrinol.Metab.
    3. (1979). Acute hyperinsulinemia and its reversal by vagotomy following lesions of the ventromedial hypothalamus in anesthetized rats.
    4. (1993). Adrenoceptor subtypes mediating catecholamineinduced thermogenesis in man.
    5. (1985). An hypothesis on the aetiology of obesity:dysfunction of the central nervous system as a primary cause.
    6. and Hamilton,J.K.(2010).Evaluationof a comprehensive care clinic model for children with brain tumor and risk for hypothalamic obesity.
    7. and Imura,H.(1987).Vagalregulationof insulin, glucagon, and somatostatin secretion in vitro in the rat.
    8. (1994). aninositol1,4,5-triphosphate-sensitive Ca2+ store in secretory granules of insulinproducing cells.
    9. (2003). Autonomic dysfunction of the (ß-cell and the pathogenesis of obesity.
    10. (2000). Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression.
    11. (2000). Central nervous system control of food intake.
    12. (2008). Childhood craniopharyngioma: recent advances in diagnosis, treatment and follow-up.
    13. (1988). Children with craniopharyngioma: early growth failure and rapid post-operative weight gain.
    14. (1980). Consequences of ventromedial hypothalamic lesions upon insulin and glucagon secretion by subsequently isolated perfused pancreases in the rat.
    15. (2009). Craniopharyngioma and hypothalamic obesityinchildren.ChildsNerv.Syst.
    16. (2002). Craniopharyngioma: the St. Jude Children’s Research Hospital experience 1984–2001.
    17. (2003). Defect in epinephrine production in children withcraniopharyngioma:functional ororganicorigin?J.Clin.Endocrinol.
    18. Delayed ghrelin suppression following oral glucose tolerance test in children and adolescents with hypothalamic injury secondary to craniopharyngioma compared with obese controls.
    19. (1980). Diabetic syndrome in the Chinese hamster induced with monosodium glutamate.
    20. (2005). Divergence of melanocortin pathways in the control of food intake and energy expenditure.
    21. (1901). Ein fall von tumor der hypophysis cerebri ohne akromegalie.
    22. (2005). Endocrine and neuroanatomic predictors of weight gain and obesity in adult patients with hypothalamic damage.
    23. (2004). Features of the metabolic syndrome after craniopharyngioma.J.Clin.Endocrinol.Metab.89,
    24. (2007). First experiences with laparoscopic adjustable gastric banding (LAGB) in the treatment of patients with childhood craniopharyngioma and morbid obesity.
    25. (1999). From lesions to leptin: hypothalamic control of food intake and body weight.
    26. (1998). from the dorsomedial and ventromedial hypothalamic nuclei.
    27. (2000). Ghrelin induces adiposity in rodents.
    28. (1976). Glucose intolerance and insulin release, a mathematical approach.1. Assay of the beta cell response after glucose loading.
    29. (2004). Gut hormones and the control of appetite.
    30. Hochberg, Z.(2003).11β-hydroxysteroiddehydrogenase activity in hypothalamic obesity.
    31. (2000). Hormonal factors influencing weight and growth pattern in craniopharyngioma.
    32. (2011). Hypothalamic obesity after craniopharyngioma: mechanisms, diagnosis, and treatment.
    33. (2011). Hypothalamic obesity following craniopharyngioma surgery: results of a pilot trial of combined diazoxide and metformin therapy.
    34. (1999). Hypothalamic obesity in children caused by cranial insult: altered glucose and insulin dynamics, and reversal by a somatostatin agonist.
    35. (1981). Hypothalamic obesity.
    36. (2007). Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes.
    37. (2004). In vivo epinephrinemediated regulation of gene express in human skeletal muscle.
    38. (2010). Insulin sensitivity and secretion in children and adolescents with hypothalamic obesity following treatment for craniopharyngioma.
    39. (1999). Insulin sensitivity indices obtainedfromoralglucosetolerance testing: comparison with the euglycemicinsulinclamp.DiabetesCare 22,
    40. (1995). Insulin-induced sympathetic activation and vasodilation in skeletal muscle. Effects of insulin resistance in lean subjects.
    41. (1999). Interacting appetiteregulating pathways in the hypothalamic regulation of body weight.
    42. (1995). Interrelationshipsamongmeasuresof autonomic activity and cardiovascular risk factors during orthostasis and the oral glucose tolerance test.
    43. (1994). Intracerebroventricular insulin produces non-uniform regional increases in sympathetic nerve activity.
    44. (1985). Involvement of the cholinergic system in insulin and glucagon oversecretion of genetic preobesity.
    45. (1984). Long-term follow-up of children with craniopharyngioma.
    46. (2004). Longitudinal study of growth and body mass index before and after diagnosis of childhood craniopharyngioma.J.Clin.Endocrinol.Metab.89,
    47. Lustig,R.H.(2006).Childhoodobesity: behavioral aberration or biochemicaldrive?Reinterpretingthefirstlaw ofthermodynamics.Nat.Clin.Pract.
    48. (1975). Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature.
    49. (1998). MARCKS, membranes, and calmodulin: kinetics of their interaction.
    50. (2001). Mechanisms and physiological significance of the cholinergic control ofpancreaticβ-cellfunction.Endocr.
    51. (1996). Mechanisms of inhibition of insulin release.
    52. (1996). Muscarinic stimulation increases Na+ entry in pancreatic β-cells by a mechanism other than the emptying of intracellular Ca2+ pools.
    53. (1981). Neural pathways involved in the hypothalamic integration of autonomic responses.
    54. (2003). Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity.
    55. (2005). Obesity in pediatric oncology.
    56. (2003). Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial.
    57. (2011). paper pending published: 29
    58. (1997). Pathophysiological significance of the obese gene product, leptin in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats.
    59. (1998). Pilot study of evaluation andtreatmentof tumor-relatedobesity in pediatric patients with hypothalamic/chiasmatic gliomas and craniopharyngiomas,”
    60. (2000). Postoperative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM
    61. (1996). Protein kinase C in β-cells: expression of multiple isoforms and involvement in cholinergic stimulation of insulin secretion.
    62. (2005). Racial and etiopathologic dichotomies in insulin secretion and resistance in obese children.
    63. Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma.
    64. (2008). Reductions in basal metabolic rate and physical activity contribute to hypothalamic obesity.
    65. (1997). Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement.
    66. (2003). Risk factors for the development of obesity in children surviving brain tumors.
    67. (1996). Role of leptin in fat regulation.
    68. (2003). Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin.
    69. (1999). Role of the β3-adrenergic receptor and/or a putative β3-adrenergic receptor on the expression of uncoupling proteins and peroxisome proliferatoractivated receptor-g coactivator-1.
    70. (2010). Sleep-disordered breathing is increased in obese adolescents with craniopharyngioma compared with obese controls.
    71. (1984). Syndromes of hypothalamic obesity in man.
    72. (1995). Targeted disruption of the beta 3-adrenergic receptor gene.
    73. (2007). The efferent arm of the energy balance regulatory pathway: neuroendocrinology and pathology,”
    74. (1999). The glucagon-like peptides.
    75. (2002). The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma.
    76. (2000). Towards a molecular understanding of adaptive thermogenesis.
    77. (2009). Treatment of hypothalamic obesity by laparoscopictruncalvagotomy:earlyexperience,”
    78. (1983). Truncal vagotomy in hypothalmic obesity.
    79. (2011). Tschöp, M.H.(2007).Gastricbypasssurgery for treatment of hypothalamic obesity after craniopharyngioma therapy.
    80. (1900). Tumeur du corps pituitaire san acromegalie et avec arret de developpement des organes genitaux.
    81. (1978). Ventromedial hypothalamus modulates fat mobilization during fasting.
    82. (2011). Von Zur Muhlen, A., andBrabant,G.(2002).Sympathoadrenal counterregulation in patients with hypothalamic craniopharyngioma.J.Clin.Endocrinol.Metab.87,

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.